Nidec Announces in Relation to Disclosure Information Regarding Consolidated Financial Statements
KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation hereby announces that at the Board of Directors meeting held today, it was resolved to post the contents of the attachment on its Internet website (address: https://www.nidec.com/en/ir/event/meeting/).
The audits of overseas subsidiaries are taking time, and we have not yet received the accounting auditor's report on the consolidated financial statements.
The accounting auditor's report on the consolidated financial statements is currently being prepared in time for the 52nd Annual General Meeting of Shareholders, scheduled to be held on June 20, 2025, but is yet to be determined. We will notify you as soon as we receive it.
(Attachment)
To our shareholders
Disclosure information regarding consolidated financial statements
We would like to express our sincere gratitude to our shareholders for their ongoing support and encouragement.
Our 52nd business report, financial statements, and consolidated financial statements have already been submitted to the Audit and Supervisory Committee and the accounting auditor. However, due to the time required for the audits of our overseas subsidiaries, we have not yet received the accounting auditor's audit report on the consolidated financial statements.
We have already sent the materials for the 52nd Annual General Meeting of Shareholders to shareholders who have requested to receive them in writing. These materials include the accounting auditor's audit report on the consolidated financial statements and the audit report of the Audit and Supervisory Committee, the contents of which are subject to receipt of the accounting auditor's audit report. These audit reports were prepared and sent in anticipation of receiving the accounting auditor's audit report on the consolidated financial statements. However, as stated above, we have not yet received the accounting auditor's audit report on the consolidated financial statements at this time.
In this regard, the audit reports of the Audit and Supervisory Committee, which are based on the assumption that the audit report of the accounting auditor on the consolidated financial statements has not yet been received at this time, are posted on the websites listed in the notice of the meeting. In addition, once the accounting auditor's audit report on the consolidated financial statements has been received and the Audit and Supervisory Committee's audit based on said audit report has been completed, the Audit and Supervisory Committee's audit report and the accounting auditor's audit report on the consolidated financial statements will be posted on the website.
Furthermore, based on the results of the accounting audits conducted by the accounting auditors for the consolidated financial statements, if any corrections are made to the information to be disclosed in the consolidated financial statements going forward, we will take measures such as promptly posting such corrections on our website (address: https://www.nidec.com/en/ir/event/meeting/). We would appreciate your understanding and cooperation in this matter.
Representative Director and President
NIDEC Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
24 minutes ago
- Business Wire
Hagens Berman Responds to Appeals to NCAA College Athlete Name, Image and Likeness Settlement
OAKLAND, Calif.--(BUSINESS WIRE)--Following the federal court's final approval to a historic $20 billion plus settlement with the NCAA allowing payments and benefits to college athletes for the use of their name, image and likeness (NIL), Hagens Berman responded to the first appeal. 'If these lawyers believe that a Title IX case will succeed, they should bring it and not hijack payments to college athletes that could be lifechanging.' To address questions from NCAA athletes about the impact of the appeal, Hagens Berman issued the following statement: 'Attorneys John Clune and Ashlyn Hare of Hutchinson Black and Cook LLC and Rebecca Peterson-Fisher of Katz Banks Kumin LLP have filed a notice of their intent to appeal the historic NCAA settlement approved June 6, 2025, by Judge Claudia Wilken. 'This appeal will block payments to hundreds of thousands of athletes, delaying payments by a minimum of several months to potentially a year or more. These attorneys are pursuing an appeal based on a Title IX issue that Judge Wilken already disposed of correctly, quickly and multiple times. 'Judge Wilken noted that these attorneys cited 'no authority that Title IX applies to damages awards distributions or that damages distributions made by a claims administrator are subject to Title IX.'' 'This is an antitrust case about competition, it is not a Title IX case, and now hundreds of thousands of athletes will have to wait to recover for past wrongs that were addressed in this lawsuit in order for these attorneys to take on this unrelated issue,' added Hagens Berman co-founder and managing partner, Steve Berman, who serves as court-appointed co-lead counsel. 'If these lawyers believe that a Title IX case will succeed, they should bring it and not hijack payments to college athletes that could be lifechanging.' Straight from the Bench In Judge Wilken's June 6, 2025, opinion on the order granting final approval to the settlement, the court clearly states that it overrules objections, noting, 'There is nothing in the SA [settlement agreement] that would prevent or prohibit schools from distributing benefits and compensation pursuant to the Injunctive Relief Settlement in a manner that complies with Title IX.' Berman added, 'Judge Wilken had made that same ruling earlier in the case, theoretically allowing objectors ample time to find authority to back up their objection, and they failed. It's a shame given this utter failure they will be holding up payments to athletes. I say shame on them.' Hagens Berman represents a class of nearly 400,000 college athletes in the lawsuit in which the total value under the new revenue-sharing model is expected to exceed $20 billion over the next 10 years. The settlement resolves three pending antitrust lawsuits, House v. NCAA, Hubbard v. NCAA, and Carter v. NCAA. Class members in the three affected cases may find out more about the claim process by visiting the settlement website at . Hagens Berman is a global plaintiffs' rights complex litigation law firm with a tenacious drive for achieving real results for those harmed by corporate negligence and fraud. Since its founding in 1993, the firm's determination has earned it numerous national accolades, awards and titles of 'Most Feared Plaintiff's Firm,' MVPs and Trailblazers of class-action law. More about the law firm and its successes can be found at Follow the firm for updates and news at @ClassActionLaw.
Yahoo
35 minutes ago
- Yahoo
Establishment Labs Hosting Investor Day on June 12
NEW YORK, June 11, 2025--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at In-person attendance at the event is limited and requires advanced registration. Please email: ir@ for further information. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at View source version on Contacts Investor/Media Contact: Raj Denhoy415 828-1044rdenhoy@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
40 minutes ago
- Business Wire
Establishment Labs Hosting Investor Day on June 12
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at In-person attendance at the event is limited and requires advanced registration. Please email: ir@ for further information. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at
